News and Trends 25 May 2023 PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […] May 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 Major progress as Swedish scientists get brain tumors to self destruct Researchers at the University of Gothenburg in Sweden, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma. By blocking certain functions in the cell with a docked molecule, the researchers cause the cancer to die of stress.Cancer cells, especially those that form aggressive tumors, are in one […] May 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 FDA approval for Rznomics’ glioblastoma treatment trial Rznomics Inc., a South Korea based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, has received phase 1/2a IND approval from the U.S. FDA for its glioblastoma multiforme (GBM) treatment. RZ-001 initially obtained IND approval for hepatocellular carcinoma (HCC), but Rznomics also found pre-clinical efficacy in GBM models and submitted the IND for […] May 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2023 Cancer implications as new molecule can kill ‘zombie’ cells Over time, the body’s cells stop working properly and begin to accumulate, which eventually leads to tissues aging. Researchers at the UOC (Universitat Oberta de Catalunya) in Spain, in collaboration with the University of Leicester in the U.K. have discovered a new molecule that is able to destroy these old cells without affecting healthy ones. […] May 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2023 Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment Kelonia Therapeutics, a biotech company working on in vivo gene delivery, has announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs). Kelonia’s iGPS platform enables CAR T cell therapy […] May 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2023 Researchers make cancer weight loss pathway discovery Nearly half of all cancer patients suffer from excessive weight loss due to the loss of adipose and skeletal muscle tissues, or cachexia. This progressive illness not only reduces quality of life for cancer patients but also poses a serious threat for treatment since it obstructs the use of effective medicines, especially in advanced stages. […] May 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Could a salt flats pigment treat cancer? Researchers have identified the anti-cancer capacity of a pigment present in the Santa Pola salt flats in eastern Spain. The pigment is produced by certain microorganisms, the ‘halophilic archaea’, in order to protect themselves from the sun, and its anti-tumor capacity has been tested in several types of breast cancer. The study took place at […] May 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 LabGenius looks to create molecules with huge increase in tumor killing ability LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2023 Achilles Therapeutics’ new platform identifies most potent T-cell antigens Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […] May 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2023 Scientists create first CRISPR-based drug candidate targeting the microbiome A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections. Many people have experienced infections from E. coli, which are […] May 10, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 May 2023 5 cancers that immunotherapy can cure Cancer immunotherapy dates back to 1891, when William Coley became the first person to try and harness the immune system to treat cancer. Since then, immunotherapy has become the mainstay of cancer treatment and is being used in the fight against many different types of cancer. When the first immune checkpoint inhibitor – which works […] May 9, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Gilead boosts oncology pipeline with XinThera acquisition Gilead Sciences, Inc. has announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. Gilead Sciences said the acquisition complements its existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead Sciences gains the rights to a portfolio […] May 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email